Ideaya Biosciences
Clinical trials sponsored by Ideaya Biosciences, explained in plain language.
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 17, 2026 04:10 UTC
-
New hope for rare eye cancer: drug duo targets hard-to-treat melanoma
Disease control OngoingThis study tests a new combination of two drugs (IDE196 and crizotinib) against standard treatments for people with a rare eye cancer called uveal melanoma that has spread to other parts of the body. It includes 420 adults whose cancer cells lack a specific marker (HLA-A2 negativ…
Phase: PHASE2, PHASE3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New pill could shrink eye tumors and save patients from eye removal
Disease control OngoingThis study tests a drug called darovasertib in 160 people with a rare eye cancer (uveal melanoma). The goal is to shrink tumors so that some patients can avoid losing their eye and instead receive radiation. The drug is taken by mouth and aims to control the cancer, not cure it, …
Phase: PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control OngoingThis early-phase study tests an experimental drug called IDE397 in adults with advanced solid tumors that have a specific genetic deletion (MTAP-deleted) and have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumo…
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 01, 2026 18:07 UTC